SCHEMBL2082136

SCHEMBL2082136

Cc1c(CO)ncn1COCC[Si](C)(C)C

nearest known ligand 0.40

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 8/20 0.38
USP2 O75604 1/20 0.32
PNP P00491 1/20 0.32
TSHR P16473 1/20 0.32
EDNRA P25101 1/20 0.32
HTR2A P28223 1/20 0.32
RECQL P46063 1/20 0.32
BLM P54132 1/20 0.32
HBB P68871 1/20 0.32
HSD17B10 Q99714 1/20 0.32
BRD4 O60885 1/20 0.30
CREBBP Q92793 1/20 0.30
PDE10A Q9Y233 1/20 0.30
KLKB1 P03952 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14435378 0.86 DGAT1 (0.38) DGAT1BRD4CREBBPPDE10A
SCHEMBL24102662 0.85 DGAT1 (0.38) DGAT1BRD4CREBBPPDE10A
SCHEMBL31631877 0.85 DGAT1 (0.38) DGAT1BRD4CREBBPPDE10A
SCHEMBL3529044 0.84 DGAT1 (0.37) DGAT1USP2PNPTSHREDNRA
SCHEMBL31631868 0.82 DGAT1 (0.36) DGAT1
SCHEMBL12118691 0.81 DGAT1 (0.44) DGAT1BRD4CREBBP
SCHEMBL13722210 0.81 DGAT1 (0.40) DGAT1BRD4CREBBPPDE10AKLKB1
SCHEMBL15694427 0.79 DGAT1 (0.38) DGAT1USP2PNPTSHREDNRA
SCHEMBL17675396 0.78 DGAT1 (0.39) DGAT1BRD4CREBBPKLKB1
SCHEMBL2822527 0.78 DUT (0.39) DGAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025125665-A1 FURTHER SUBSTITUTED IMIDAZOLES AS INHIBITORS OF NAV1.8 Grünenthal GmbH (DE) 2025-06-19 WO disclosed
WO-2025077825-A1 METHODS AND COMPOSITIONS FOR TREATING CARDIO-PULMONARY DISORDERS FAUNA BIO INCORPORATED (US) 2025-04-17 WO disclosed
EP-1613613-B1 CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS GENZYME CORP (US) 2021-06-02 EP disclosed
US-7863293-B2 CXCR4 chemokine receptor binding compounds GENZYME CORPORATION (US) 2011-01-04 US disclosed
EP-1613613-A4 CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS ANORMED INC (CA) 2009-03-25 EP disclosed
US-20080255197-A1 CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS ANORMED CORPORATION (CA) 2008-10-16 US disclosed
US-7291631-B2 CXCR4 chemokine receptor binding compounds GENZYME CORPORATION (US) 2007-11-06 US disclosed
EP-1613613-A2 CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS ANORMED INC. (CA) 2006-01-11 EP disclosed
WO-2004091518-A2 CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS ANORMED INC. (CA) 2004-10-28 WO disclosed
US-20040209921-A1 CXCR4 chemokine receptor binding comounds ANORMED CORPORATION (CA) 2004-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040209921-A1 CXCR4 chemokine receptor binding comounds CXCR4, CXCR1, CXCR3 DGAT1 3278/4885USP2 4210/4885PNP 2336/4885
US-20080255197-A1 CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS CXCR4, CXCR1, CXCR3 DGAT1 3121/4885USP2 4136/4885PNP 1673/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.